139 related articles for article (PubMed ID: 38695142)
1. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Renaud L; Wencel J; Pagès A; Al Jijakli A; Moatti H; Quero L; Camus V; Brice P
Haematologica; 2024 May; ():. PubMed ID: 38695142
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Santoro A; Moskowitz AJ; Ferrari S; Carlo-Stella C; Lisano J; Francis S; Wen R; Akyol A; Savage KJ
Blood; 2023 Jun; 141(22):2780-2783. PubMed ID: 36898084
[No Abstract] [Full Text] [Related]
7. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Lisano J; Wen R; Akyol A; Moskowitz AJ
Blood Adv; 2023 Sep; 7(18):5272-5280. PubMed ID: 37352266
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV; Lepik KV; Volkov NP; Kotselyabina PV; Borzenkova ES; Popova MO; Beynarovich AV; Baykov VV; Kozlov AV; Moiseev IS; Mikhailova NB; Kulagin AD
Int J Clin Oncol; 2022 Mar; 27(3):626-632. PubMed ID: 34826011
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
18. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin treatment for primary refractory hodgkin lymphoma.
Wu HB; Yeh SA; Chen HY
Case Rep Hematol; 2013; 2013():351292. PubMed ID: 24198983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
